2022
Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagement
2020
Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
Barocas JA, Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clinical Infectious Diseases 2020, 73: e3661-e3669. PMID: 32901815, PMCID: PMC8662770, DOI: 10.1093/cid/ciaa1346.Peer-Reviewed Original ResearchConceptsInjection opioid useRisk of deathAge 60 yearsOpioid useInfective endocarditisOpioid epidemicMortality rateUS opioid epidemicSyringe services programLow-risk techniqueProbability of deathHarm reduction approachAttributable fractionRisk groupsNatural historyInjection behaviorModel-generated estimatesDeathOpioidsSignificant increaseInjection frequencyUnited StatesMortalityRiskEpidemic